TAVNEOS (avacopan) Recall: Health Canada Reviews Data Integrity Concerns
Areazine synthesizes this Health Canada recall directly from Health Canada's official public data feed. See our methodology for full source attribution and refresh cadence.
Health Canada is reviewing significant data integrity concerns from the ADVOCATE trial supporting TAVNEOS (avacopan) authorization, raising questions about efficacy.
What this Health Canada recall tells you, and what most readers miss
This notice was issued by Health Canada on August 2, 2026 and geographically references Canada. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Product & Food Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, health-canada, Medication.
What Happened
Health Canada has identified significant concerns about the data that supported the authorization of TAVNEOS (avacopan). These concerns raise questions about the efficacy of TAVNEOS. The authorization of TAVNEOS in Canada (April 2022) was supported primarily by the pivotal Phase 3 ADVOCATE trial.
Which Products Are Affected
TAVNEOS (avacopan) capsules, 10 mg. TAVNEOS is indicated for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard background therapy including glucocorticoids.
What You Should Do
Healthcare professionals are advised to: NOT initiate treatment with TAVNEOS in new patients. Contact and monitor patients currently receiving TAVNEOS and assess whether continued treatment remains appropriate.
Why This Matters
Pending the outcome of Health Canada’s review of these concerns, there is uncertainty about the reliability of the efficacy evidence supporting the product’s benefit-risk profile.
Source
https://recalls-rappels.canada.ca/en/alert-recall/tavneos-avacopan-and-health-canada-s-review-data-integrity-concerns - Health Canada
Original source: Health Canada Official Notice ↗
Related Product & Food Recalls
All Product & Food Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this Health Canada recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,270 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to August 2, 2026.
Frequently Asked Questions
Common questions about this Health Canada recall.